As both SYK inhibitors fostamatinib and entospletinib are capable of blocking phagocytosis (103, 104), whether these compounds can curb SARS-CoV-2 uptake and subsequent pyroptosis in COVID-19 is of interest for further exploration. This evidence concerns the gene SYK and COVID-19.